YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
UroGen Pharma URGN is emerging as a commercial-stage biotech with an expanding presence in uro-oncology. The company has two marketed products, Zusduri and Jelmyto, and a pipeline that could support additional growth in bladder cancer and…
UroGen Pharma (NASDAQ:URGN) operates as a specialized oncology and urology therapeutics company anchored by proprietary sustained-release technology platforms. By developing localized drug delivery systems designed to retain therapeutics i…
Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer. Continue Reading
Last week, major U.S. indexes like the Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average have modestly gained by 0.52%, 0.42%, and 0.43%, respectively. Economic conditions remained complicated because of geopolitical tensi…
[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [http…
Healthcare stocks were mixed Monday afternoon, with the NYSE Healthcare Index up nearly 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) fractionally lower.The iShares Biotechnology ETF (IBB) climbed up 1.8%.In corporate…
(RTTNews) - Today's top biotech gainers include Attovia Therapeutics, which surged following its Nasdaq debut; American Well, after reporting a narrower loss; Perrigo, which swung back to profit; and UroGen Pharma, following strong second-…
Major earnings expected before the bell on Wednesday include: * The Walt Disney Company (DIS [https://seekingalpha.com/symbol/DIS]) * Eli Lilly and Company (LLY [https://seekingalpha.com/symbol/LLY]) * Shopify (SHOP [https://seekingalpha.c…
Insmed (INSM) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture…
Key Points According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as repo…
Mark Schoenberg, Chief Medical Officer, sold 10,000 ordinary shares of UroGen Pharma Ltd. (NASDAQ:URGN) on July 9, 2026, for a total value of $400,000, according to an SEC Form 4 filing. Transaction summary Metric Value Transaction value $…
(RTTNews) - Even with strong research and disciplined stock selection, an investor may not get every stock pick right. As legendary investor Peter Lynch once said, "In this business, if you're good, you're right six times out of ten. You'r…
Key Points 10,000 shares were sold for a transaction value of ~$350,000 at a weighted average price of around $35.01 per share on June 22, 2026. The sale represented 7.15% of Mark Schoenberg's direct holdings, reducing his position from 13…
The non-muscle invasive bladder cancer market is witnessing significant growth due to the rising global incidence of bladder cancer, advancements in immunotherapy, targeted treatments, and launch of novel therapies such as CG0070 (cretosti…
Key Points 5,222 shares were sold on June 8, 2026 for a transaction value of approximately $143,000 at a weighted average price around $27.30 per share. The transaction represented 3.60% of Mark Schoenberg's direct holdings, reducing his p…
Mark Schoenberg, Chief Medical Officer of UroGen Pharma Ltd.(NASDAQ:URGN), reported the sale of 5,222 ordinary shares for a total of approximately $143,000, as disclosed in a SEC Form 4 filing. Transaction summary Metric Value Shares sold…
In June 2026, UroGen Pharma Ltd. and UroGen Pharma Inc. announced a settlement and license agreement with Teva Pharmaceuticals resolving U.S. patent litigation over Jelmyto, granting Teva a non-exclusive license to sell a generic version f…
UroGen Pharma Ltd. Agreement reinforces the value of UroGen’s innovation and reflects the strength of the Company’s intellectual property portfolio Teva will be granted a non-exclusive license to sell its generic version of JELMYTO beginni…
ImmunityBio IBRX is trying to turn a persistent bottleneck in bladder cancer care into a durable demand driver. The long-running U.S. Bacillus Calmette-Guérin (BCG) shortage has created a structural “pull” for regimens that can improve tre…
Key Points Superstring Capital sold 330,983 shares of UroGen Pharma Ltd last quarter; the estimated transaction value was $6.64 million based on quarterly average pricing. The quarter-end position value decreased by $9.86 million, reflecti…
Superstring Capital Management cut its stake in UroGen Pharma Ltd. (NASDAQ:URGN), selling 330,983 shares in the first quarter in an estimated $6.64 million trade based on average quarterly pricing, according to a May 14, 2026, SEC filing.…
Key Points Superstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices. The quarter-end position value rose $6.55 million, reflecting the new s…
Superstring Capital Management disclosed a new position in Vir Biotechnology(NASDAQ:VIR), acquiring 730,548 shares in the first quarter. The estimated transaction value was $5.82 million based on quarterly average pricing. What happened Ac…
Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street H PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Most stock indexes ended the week lower as investor sentiment remained cautious due to Iran conflict risks, inflation concerns, and weaker Wall Street trends after a hotter-than-expected U.S. inflation report. Tensions also rose after the…
PRINCETON, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company focused on transforming the treatment of urothelial and specialty cancers, today announced UGN-103 achieved a 94.5% (95% CI: 86.1,…
Earnings Call Insights: UroGen Pharma (URGN) Q1 2026 MANAGEMENT VIEW * “Given the critical importance of a successful ZUSDURI launch, the Board and I made the decision a few months ago that I would assume direct oversight of the commercial…
Urogen Pharma (URGN) came out with a quarterly loss of $0.47 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.92 per share a year ago. These figures are adjusted for non-recurring items. This…
Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.2 per share a year ago. These figures are adjusted for non-recurring it…
ImmunityBio IBRX enters 2026 with a commercial story that is unusually concentrated. Anktiva is the company’s first marketed product, and it is already the clear topline driver. What matters now is whether demand signals from the U.S. laun…
On February 17, 2026, Acorn Capital Advisors reported selling 225,000 shares of Terns Pharmaceuticals(NASDAQ:TERN), an estimated $5.20 million trade based on quarterly average pricing. What happened According to a filing with the Securitie…
On February 17, 2026, Superstring Capital Management disclosed a new position in Axsome Therapeutics(NASDAQ:AXSM), acquiring 37,433 shares worth $6.84 million in the fourth quarter. What happened According to a Securities and Exchange Comm…
Superstring Capital Management initiated a new position in Sionna Therapeutics(NASDAQ:SION), acquiring 180,593 shares in the fourth quarter. What happened According to a February 17, 2026, SEC filing, Superstring Capital Management reporte…
On February 17, 2026, Superstring Capital Management disclosed a new position in Definium Therapeutics(NASDAQ:DFTX), acquiring 425,202 shares in the fourth quarter. What happened According to a SEC filing dated February 17, 2026, Superstri…
On February 17, 2026, Superstring Capital Management reported selling 345,869 shares of Terns Pharmaceuticals(NASDAQ:TERN) in the fourth quarter, an estimated $7.99 million trade based on quarterly average pricing. What happened According…
Urogen Pharma logo Key Points Zusduri launch is gaining momentum after the permanent J-code (effective Jan. 1), with management reporting $15.8M in Zusduri revenue in 2025, acceleration in new/repeat prescribers and patient starts, 838 act…